[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"retina-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:retina-disorder":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100648790","aoslo-imaging-for-the-study-of-cellular-alterations-in-retinal-neurodegeneration-100648790",false,"NCT07725055","AOSLO Imaging for the Study of Cellular Alterations in Retinal Neurodegeneration","RETION","Inclusion Criteria:\n\nPatients:\n\n* 100 subjects aged 10 to 79 years with a condition that may affect the inner retina (e.g., glaucoma, optic neuropathy, etc.)\n* 100 subjects aged 10 to 80 years with a condition that may affect the outer retina (e.g., AMD, retinitis pigmentosa, etc.)\n* Male or female\n* Covered by health insurance\n\nHealthy volunteers:\n\n* 30 subjects aged over 50 and under 80\n* 30 subjects aged over 18 and under 50\n* Male or female\n* Healthy subjects with no known condition that directly or indirectly affects the structure of the eye\n* Covered by health insurance\n\nExclusion Criteria:\n\nFor all subjects:\n\n* Inability to remain motionless on a standard ophthalmic chin rest. RETION\\_Protocol\\_v2.0 dated June 10, 2026\\_IDRCB: 2026-A00324-47 Page 10 of 44\n* Subjects taking medications or suffering from a medical condition that could interfere with the evaluations planned under the protocol;\n* Participants allergic to tropicamide in cases where pupil dilation is required. ☞ Wearing glasses or contact lenses to correct a refractive error is not considered an exclusion criterion.",true,"ALL","10 Years","79 Years",{"count":21,"type":22},260,"ESTIMATED","INTERVENTIONAL",[25],"NA","Primary objective:\n\n\\- Acquisition and analysis of images for non-medical purposes using the MONA IV system, an adaptive-optics-corrected scanning ophthalmoscope.\n\nSecondary objectives:\n\n* To measure the reproducibility of assessments;\n* To evaluate the detection of progressive changes.",[28,29],"Glaucoma Associated With Other Ocular Disorders","Retina Disorder",[14],"NOT_YET_RECRUITING","2026-07-21",{"date":34,"type":35},"2026-07-24","ACTUAL",{"date":37,"type":22},"2026-09",{"date":39,"type":22},"2030-04",{"name":41,"class":42},"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100599312","phase-3-a-multicenter-randomized-double-blind-controlled-clinical-study-of-minocycline-for-the-treatment-of-retinitis-pigmentosa-100599312","NCT07082855","A Multicenter, Randomized, Double-Blind, Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa","A Multicenter, Double-Blind, Randomized Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa","Inclusion Criteria:\n\n* Age should be between 18 and 60 years old.\n* Clinically diagnosed with retinitis pigmentosa, characterized by reduced electroretinogram (ERG) responses and constricted visual fields.\n* In at least one eye, the amplitude of the 30Hz flicker ERG under photopic conditions should not be lower than 0 microvolts.\n* The best-corrected visual acuity (BCVA, ETDRS) in both eyes should not be lower than 0.\n\nExclusion Criteria:\n\n* Allergic to tetracycline antibiotics.\n* Pregnant or breastfeeding.\n* Syndromic retinitis pigmentosa.\n* Currently taking tetracycline antibiotics or any medications that may have adverse interactions with minocycline.\n* Currently participating in or having participated in another investigational study within the past 6 months.\n* Presence of other ocular diseases, including glaucoma, uveitis, age-related macular degeneration, diabetic retinopathy, etc.\n* History of ocular surgical intervention.\n* History of uncontrolled severe comorbid conditions, such as renal disease, liver disease, autoimmune disease, thyroid dysfunction, psychiatric disorders, or idiopathic intracranial hypertension.\n* Inability of the participant to comply with the study-required procedures, such as epilepsy, inability to fixate, or allergy to fluorescein. Inability to understand the content of the study, sign the informed consent form, or comply with the study procedures or follow-up visits.\n* Inability to swallow capsules.","18 Years","60 Years",{"count":53,"type":22},126,[55],"PHASE3","This is a multicenter, double-blind, randomized controlled clinical trial to get high - level evidence on minocycline's efficacy and safety（100mg\u002Fd, 200mg\u002Fd) for Retinitis pigmentosa and to find the optimal treatment dose.",[58,59,29],"Retinitis Pigmentosa","Inherited Retinal Dystrophy",[58,61,62,59],"Minocycline","ERG","2025-07-15",{"date":65,"type":35},"2025-07-24",{"date":63,"type":22},{"date":68,"type":22},"2028-06-30",{"name":70,"class":42},"Zhongshan Ophthalmic Center, Sun Yat-sen University",1]